Lexicon Pharmaceuticals

The SOTA P CARDIA trial demonstrated that sotagliflozin treatment resulted in statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test capacity, and quality of life measures in HFpEF patients without diabetes.

Lexicon Pharmaceuticals presented patient survey data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience to inform development of pilavapadin.

DelveInsight's 2025 pipeline analysis reveals a robust heart failure therapeutic landscape with over 70 companies developing 75+ pipeline therapies across various stages of clinical development.

Lexicon Pharmaceuticals has launched SONATA-HCM, the only ongoing Phase 3 trial evaluating sotagliflozin in both obstructive and non-obstructive hypertrophic cardiomyopathy, with enrollment active across 20 countries.

Lexicon Pharmaceuticals' non-opioid painkiller pilavapadin failed to achieve statistical significance versus placebo in Phase IIb RELIEF-DPN-1 trial for diabetic neuropathy pain.

A landmark clinical trial led by Mount Sinai researchers demonstrates that sotagliflozin, a dual SGLT1/2 inhibitor, reduces heart attacks, strokes, and cardiovascular deaths by 23% in patients with type 2 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals' LX9211, a non-opioid therapy, completed Phase 2b trial for diabetic peripheral neuropathic pain, exceeding enrollment targets due to high interest.

Lexicon Pharmaceuticals will host a virtual webcast on January 28, 2025, featuring an in-depth discussion of LX9211, their investigational non-opioid treatment for diabetic peripheral neuropathic pain.

• The FDA is set to decide on Ionis Pharmaceuticals' olezarsen for familial chylomicronemia syndrome (FCS), a rare genetic disease, by December 19, following positive Phase III results. • Lexicon Pharmaceuticals awaits the FDA's decision on sotagliflozin as an adjunct therapy for type 1 diabetes by December 20, despite concerns raised by an advisory committee. • AstraZeneca and Daiichi Sankyo's Dato-DXd for non-squamous NSCLC is under FDA review, with a decision expected by December 20, based on Phase III data showing progression-free survival benefits. • Neurocrine Biosciences anticipates FDA decisions on crinecerfont for congenital adrenal hyperplasia (CAH) by December 29 and 30, potentially marking the first new treatment in 70 years.

Lexicon Pharmaceuticals has finished enrolling 494 subjects in its Phase IIb PROGRESS trial, exceeding the initial target by 20%, to evaluate LX9211 for diabetic peripheral neuropathic pain (DPNP).